NanoSphere

🟣𝗢𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗡𝗮𝗻𝗼𝗦𝗽𝗵𝗲𝗿𝗲 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 – 𝗜𝘀𝘀𝘂𝗲 𝟬𝟱 𝗶𝘀 𝗵𝗲𝗿𝗲!  🔗 Get your free copy by subscribing here: https://lnkd.in/eCyE3Pt2 𝗪𝗵𝗮𝘁’𝘀 𝗜𝗻𝘀𝗶𝗱𝗲? Every month, we bring you the latest breakthroughs in nanomedicine—from academia, industry, clinical applications, regulatory updates, and business insights—curated by our expert team: Marija Petrovic-D, PhD, Allegra Peletta, PhD, Mireya L. Borrajo, Olivera Petrovic, Ana Petkovic, and Adèle Rakotonirina, PhD. 📌 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗶𝘀 𝗲𝗱𝗶𝘁𝗶𝗼𝗻! 🔥 The hottest topics in nanomedicine 🔍 Exclusive expert insights 💡 Cutting-edge innovations 💬 Want to quickly dive into nanomedicine? 𝗧𝗿𝘆 𝗼𝘂𝗿 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, 𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝘆 𝗮 𝗖𝗵𝗮𝘁𝗚𝗣𝗧-𝗯𝗮𝗰𝗸𝗲𝗱 𝗽𝗿𝗼𝗺𝗽𝘁 𝗳𝗼𝗿 𝘀𝗺𝗮𝗿𝘁 𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝘀! ➡ https://lnkd.in/eNr_VmYG 🙏 Special thanks to our sponsors: Inside Therapeutics (InsideTx), Nawah Scientific, LitView, and Imdea for making this possible! ⚡ Stay ahead—subscribe now and never miss an update! #Nanosphere #NanomedicineNews #Biotech #MedTech #HealthcareInnovation

🟣 #BloodBrainBarrier, #mRNATherapy, #LipidNanoparticles | 𝗖𝗮𝗻 𝘄𝗲 𝘂𝗻𝗹𝗼𝗰𝗸 𝗺𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗯𝗿𝗮𝗶𝗻? 𝘛𝘩𝘪𝘴 𝘴𝘵𝘶𝘥𝘺 𝘱𝘪𝘰𝘯𝘦𝘦𝘳𝘴 𝘭𝘪𝘱𝘪𝘥 𝘯𝘢𝘯𝘰𝘱𝘢𝘳𝘵𝘪𝘤𝘭𝘦𝘴 𝘵𝘩𝘢𝘵 𝘤𝘳𝘰𝘴𝘴 𝘵𝘩𝘦 𝘣𝘭𝘰𝘰𝘥–𝘣𝘳𝘢𝘪𝘯 𝘣𝘢𝘳𝘳𝘪𝘦𝘳 (𝘉𝘉𝘉) 𝘧𝘰𝘳 𝘮𝘙𝘕𝘈 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘺 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘯𝘦𝘳𝘷𝘰𝘶𝘴 𝘴𝘺𝘴𝘵𝘦𝘮 𝗔𝗶𝗺: ✔️ Developing BBB-crossing lipid nanoparticles to enable systemic mRNA delivery into the brain, overcoming a major challenge in CNS drug development. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ✔️ 72 novel lipid structures were synthesized, leading to an optimized formulation with superior brain-targeting efficiency. ✔️ These nanoparticles successfully transfected neurons and astrocytes across the entire brain in mouse models. ✔️ They also delivered mRNA to human brain samples ex vivo, demonstrating translational potential. 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: ✔️ This innovative lipid nanoparticle platform could revolutionize mRNA-based treatments for neurological diseases. Published in Nature Materials, 17 February 2025. Check here for more: https://lnkd.in/ejzzZTEW Thank you to the authors: Chang Wang, Yonger Xue, Tamara Markovic, PhD, Haoyuan Li, @Siyu Wang, Yichen Zhong, @Shi Du, @Yuebao Zhang, @Xucheng Hou, Yang Yu, @Zhengwei Liu, @Meng Tian, @Diana Kang, Leiming Wang, @Kaiyuan Guo, @Dinglingge Cao, Jingyue Yan, @Binbin Deng, @David McComb, Ramon Parsons, Angélica Minier-Toribio, Leanne Holt, Jiayi Pan, @Alice Hashemi, Brian Kopell, Alexander Charney, Eric Nestler, Paul Peng & Yizhou Dong 🔬 Interested in the future of brain-targeted mRNA therapy? Follow us for the latest updates! 🟰 𝗙𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗼𝘀𝘁𝘀 𝗳𝗼𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/ecNd8VDP 🟰 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗳𝗼𝗿 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/eCyE3Pt2 🟰 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗯𝗹𝗼𝗴𝘀 𝗼𝗻 𝗻𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 & 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/ekJ5cHDi 🟰 𝗥𝗲𝗮𝗱 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 (𝗺𝗮𝗻𝘆 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻!): https://lnkd.in/e-vkKBe8 🟰 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀: https://lnkd.in/eDbM9PWF

🟣 “𝘕𝘢𝘯𝘰𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦 𝘪𝘴 𝘩𝘦𝘳𝘦 𝘵𝘰 𝘴𝘵𝘢𝘺, 𝘩𝘢𝘷𝘪𝘯𝘨 𝘱𝘳𝘰𝘷𝘦𝘯 𝘪𝘵𝘴 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘪𝘰𝘯 𝘵𝘰 𝘰𝘧𝘧𝘦𝘳 𝘯𝘦𝘸 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘢𝘯𝘥 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘧𝘰𝘳 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘪𝘯𝘨, 𝘵𝘳𝘦𝘢𝘵𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘪𝘯𝘨 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴 𝘵𝘩𝘢𝘵 𝘸𝘦𝘳𝘦 𝘶𝘯𝘵𝘳𝘦𝘢𝘵𝘢𝘣𝘭𝘦, 𝘢𝘯𝘥 𝘦𝘷𝘦𝘯 𝘦𝘹𝘱𝘢𝘯𝘥𝘪𝘯𝘨 𝘵𝘰 𝘪𝘯𝘥𝘪𝘷𝘪𝘥𝘶𝘢𝘭𝘪𝘻𝘦𝘥 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴. 𝘛𝘰 𝘦𝘯𝘴𝘶𝘳𝘦 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘯𝘢𝘯𝘰𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦, 𝘸𝘦 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘸𝘰𝘳𝘬 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘢𝘴 𝘢 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘧𝘪𝘤 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺 𝘵𝘰 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘦 𝘤𝘦𝘳𝘵𝘢𝘪𝘯 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 𝘢𝘯𝘥 𝘦𝘮𝘣𝘳𝘢𝘤𝘦 𝘰𝘶𝘳 𝘤𝘰𝘮𝘣𝘪𝘯𝘦𝘥 𝘴𝘵𝘳𝘦𝘯𝘨𝘵𝘩𝘴.” – Dr. Eleni Samaridou 𝗠𝗲𝗲𝘁 Eleni Samaridou – Head of Early-stage Formulation Development & Process Design at Merck KGaA. With a deep expertise in RNA therapeutics and nanoparticle-based drug delivery, she has contributed to some of the most groundbreaking advances in the field. “𝘐𝘯 2020, 𝘸𝘩𝘦𝘯 𝘊𝘖𝘝𝘐𝘋-19 𝘩𝘪𝘵, 𝘐 𝘥𝘦𝘤𝘪𝘥𝘦𝘥 𝘐 𝘸𝘢𝘯𝘵𝘦𝘥 𝘵𝘰 𝘳𝘦𝘵𝘶𝘳𝘯 𝘵𝘰 𝘌𝘶𝘳𝘰𝘱𝘦 𝘵𝘰 𝘣𝘦 𝘤𝘭𝘰𝘴𝘦𝘳 𝘵𝘰 𝘮𝘺 𝘩𝘰𝘮𝘦 𝘤𝘰𝘶𝘯𝘵𝘳𝘺 𝘢𝘯𝘥 𝘧𝘢𝘮𝘪𝘭𝘺. 𝘍𝘰𝘳 𝘵𝘩𝘪𝘴 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯, 𝘢𝘯𝘥 𝘪𝘯𝘴𝘱𝘪𝘳𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵𝘴 𝘢𝘵 𝘵𝘩𝘢𝘵 𝘵𝘪𝘮𝘦, 𝘐 𝘥𝘦𝘤𝘪𝘥𝘦𝘥 𝘵𝘰 𝘣𝘦 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘉𝘪𝘰𝘕𝘛𝘦𝘤𝘩, 𝘔𝘢𝘪𝘯𝘻, 𝘎𝘦𝘳𝘮𝘢𝘯𝘺, 𝘢𝘴 𝘢 𝘴𝘤𝘪𝘦𝘯𝘵𝘪𝘴𝘵 𝘪𝘯 𝘵𝘩𝘦 𝘌𝘢𝘳𝘭𝘺 𝘍𝘰𝘳𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 & 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘵𝘦𝘢𝘮. 𝘉𝘦𝘪𝘯𝘨 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘉𝘪𝘰𝘕𝘛𝘦𝘤𝘩, 𝘐 𝘨𝘰𝘵 𝘵𝘰 𝘣𝘦 𝘵𝘩𝘦𝘳𝘦 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘧𝘪𝘳𝘴𝘵-𝘦𝘷𝘦𝘳 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘰𝘧 𝘵𝘩𝘦 𝘊𝘰𝘮𝘪𝘳𝘯𝘢𝘵𝘺 𝘮𝘙𝘕𝘈-𝘓𝘕𝘗 𝘷𝘢𝘤𝘤𝘪𝘯𝘦 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘊𝘰𝘷𝘪𝘥-19 𝘵𝘩𝘢𝘵 𝘴𝘢𝘮𝘦 𝘺𝘦𝘢𝘳, 𝘢𝘯𝘥 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 𝘐 𝘨𝘰𝘵 𝘵𝘰 𝘣𝘦 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘥 𝘪𝘯 2 𝘧𝘢𝘴𝘤𝘪𝘯𝘢𝘵𝘪𝘯𝘨 𝘉𝘪𝘭𝘭 & 𝘔𝘦𝘭𝘪𝘯𝘥𝘢 𝘎𝘢𝘵𝘦𝘴 𝘍𝘰𝘶𝘯𝘥𝘢𝘵𝘪𝘰𝘯 𝘧𝘶𝘯𝘥𝘦𝘥 𝘱𝘳𝘰𝘫𝘦𝘤𝘵𝘴 𝘵𝘰 𝘥𝘦𝘷𝘦𝘭𝘰𝘱 𝘮𝘙𝘕𝘈-𝘓𝘕𝘗 𝘷𝘢𝘤𝘤𝘪𝘯𝘦𝘴 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘏𝘐𝘝 𝘢𝘯𝘥 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴“ – Dr. Eleni Samaridou ☑️ 𝗜𝗻 𝘁𝗵𝗶𝘀 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄, 𝘀𝗵𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗲𝘀: ✔️ Eleni`s career path ✔️ Key challenges in formulation and process development for RNA-based treatments. ✔️ The future of nanomedicine and its role in individualized therapies. 🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄: https://lnkd.in/ewtBJZGr 🟰 Follow our LinkedIn posts for research highlights: https://lnkd.in/ecNd8VDP 🟰 Subscribe to our newsletter for cutting-edge insights: https://lnkd.in/eCyE3Pt2 🟰 Read our in-depth blogs on nanomedicine & innovation: https://lnkd.in/ekJ5cHDi 🟰 Explore groundbreaking solutions from our collaborators: https://lnkd.in/eDbM9PWF What do you think is the biggest challenge in bringing nanomedicine to mainstream healthcare? Drop your thoughts in the comments! #Nanomedicine #mRNA #LipidNanoparticles #COVID19 #DrugDelivery

🟣 #Nanomedicine, #GeneTherapy, #PolymerNanoparticles | 𝗖𝗮𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗯𝗲𝗰𝗼𝗺𝗲 𝘁𝗵𝗲𝗶𝗿 𝗼𝘄𝗻 "𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗳𝗮𝗰𝘁𝗼𝗿𝗶𝗲𝘀" 𝘂𝘀𝗶𝗻𝗴 𝗽𝗼𝗹𝘆𝗺𝗲𝗿 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀? 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘱𝘰𝘭𝘺𝘮𝘦𝘳 𝘯𝘢𝘯𝘰𝘱𝘢𝘳𝘵𝘪𝘤𝘭𝘦𝘴 𝘦𝘯𝘢𝘣𝘭𝘦 𝘪𝘯 𝘷𝘪𝘷𝘰 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘱𝘳𝘰𝘵𝘦𝘪𝘯𝘴 𝘷𝘪𝘢 𝘱𝘭𝘢𝘴𝘮𝘪𝘥 𝘋𝘕𝘈 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘺. 𝗔𝗶𝗺: ✔️ This study explores the use of computationally designed polymer nanoparticles (PNPs) to deliver plasmid DNA (pDNA) for in vivo antibody production, addressing challenges in extrahepatic gene delivery. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ✔️ SAYER™-designed PNPs successfully delivered pDNA encoding for PGT121, a broadly neutralizing anti-HIV antibody. ✔️ Intravenous delivery resulted in strong serum PGT121 expression within 24 hours, outperforming other DNA-delivery systems. ✔️ Intramuscular administration achieved sustained antibody levels >56 days post-injection, with peak expression >1.0 µg/mL. ✔️ Redosing increased both antibody levels and durability, showcasing PNPs' reproducibility and optimization potential. 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: ✔️ Machine learning-driven PNP design unlocks a promising strategy for safe, effective, and long-term in vivo protein production, with potential applications beyond HIV therapy. Published on bioRxiv, February 19, 2025. Read more: https://lnkd.in/eSB7jxBt Thank you to the authors: John Fisher, Ph.D., Shannon Petersen, Olivia Heynes, Suteja Patil, @Teresa Tamayo-Mendoza, Felipe Oviedo, Gustavo Guzman, Ph.D., Jared Van Reet, Jeffrey Ting, Sean Kevlahan, Thomas X. Neenan, Shashi Murthy. 🔬 Could PNPs redefine the future of antibody therapy? Drop your thoughts in the comments! 🟰 Follow our LinkedIn posts for research highlights: https://lnkd.in/ecNd8VDP 🟰 Subscribe to our newsletter for cutting-edge insights: https://lnkd.in/eCyE3Pt2 🟰 Read our in-depth blogs on nanomedicine & innovation: https://lnkd.in/ekJ5cHDi 🟰 Read exclusive interviews with experts: https://lnkd.in/e-vkKBe8 🟰 Explore groundbreaking solutions from our collaborators: https://lnkd.in/eDbM9PWF

🟣 #Malaria #mRNA #VaccineDevelopment | 𝗖𝗮𝗻 𝗮 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻 𝗺𝗥𝗡𝗔 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗳𝗶𝗻𝗮𝗹𝗹𝘆 𝗼𝘂𝘁𝗺𝗮𝘁𝗰𝗵 𝗺𝗮𝗹𝗮𝗿𝗶𝗮? 𝘔𝘢𝘭𝘢𝘳𝘪𝘢 𝘳𝘦𝘮𝘢𝘪𝘯𝘴 𝘢 𝘨𝘭𝘰𝘣𝘢𝘭 𝘵𝘩𝘳𝘦𝘢𝘵, 𝘥𝘦𝘮𝘢𝘯𝘥𝘪𝘯𝘨 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘷𝘢𝘤𝘤𝘪𝘯𝘦 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘦𝘴. 𝗔𝗶𝗺: ✔️ This study explores an iDC-targeting mRNA vaccine to enhance immune responses against Plasmodium falciparum circumsporozoite protein (PfCSP), surpassing conventional mRNA vaccines. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ☑️ Mice immunized with MIP3α-CSP mRNA-LNP showed: Stronger CD4⁺ T cell responses. Higher anti-NANP6 antibody titers. Superior protection against P. berghei PfCSP transgenic sporozoites compared to conventional CSP mRNA-LNP. 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: ✔️ iDC-targeting mRNA vaccines could revolutionize malaria prevention by enhancing immune activation and protection. Published in npj Vaccines, 2025. Read more: https://lnkd.in/ecjeTvQV Kudos to the authors: @Sean Yanik, @Varsha Venkatesh, James Gordy, Mohamad-Gabriel Alameh, Jacob Meza, Yangchen Li, @Elizabeth Glass, @Yevel Flores-Garcia, Ying Tam, Nattawat Chaiyawong, @Deepti Sarkar, @Drew Weissman, @Richard Markham & @Prakash Srinivasan. 🟰 𝗙𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗼𝘀𝘁𝘀 𝗳𝗼𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/ecNd8VDP 🟰 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗳𝗼𝗿 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/eCyE3Pt2 🟰 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗯𝗹𝗼𝗴𝘀 𝗼𝗻 𝗻𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 & 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/ekJ5cHDi 🟰 𝗥𝗲𝗮𝗱 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 (𝗺𝗮𝗻𝘆 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻!): https://lnkd.in/e-vkKBe8 🟰 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀: https://lnkd.in/eDbM9PWF 🔬 Interested in next-gen vaccine strategies? Follow us for the latest updates!

🟣 #Nanomedicine, #CancerTherapy, #PrecisionMedicine | 𝗖𝗮𝗻 𝗥𝗚𝗗-𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗻𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁? 𝘛𝘢𝘳𝘨𝘦𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘵𝘶𝘮𝘰𝘳 𝘮𝘪𝘤𝘳𝘰𝘦𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵 (𝘛𝘔𝘌) 𝘸𝘪𝘵𝘩 𝘙𝘎𝘋-𝘥𝘦𝘤𝘰𝘳𝘢𝘵𝘦𝘥 𝘯𝘢𝘯𝘰𝘱𝘢𝘳𝘵𝘪𝘤𝘭𝘦𝘴 𝘰𝘱𝘦𝘯𝘴 𝘯𝘦𝘸 𝘧𝘳𝘰𝘯𝘵𝘪𝘦𝘳𝘴 𝘪𝘯 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺. 𝗔𝗶𝗺: ✔️ This study explores how RGD-functionalized nanoparticles selectively target integrins within the tumor microenvironment, improving drug delivery and treatment precision. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ✔️ RGD-decorated nanoparticles enhance tumor targeting by overcoming the limitations of the traditional Enhanced Permeability and Retention (EPR) effect. ✔️ These nanoparticles enable precise chemotherapeutic delivery, improving treatment efficacy for aggressive cancers. ✔️ Despite clinical challenges, RGD-based strategies hold strong translational potential, particularly in pediatric oncology. 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: ✔️ Functionalizing nanoparticles with RGD peptides offers a transformative approach to precision cancer therapy, paving the way for more effective and targeted treatments. Published in Cancer Letters, April 2025. Read the full article: https://lnkd.in/eURZhrBZ Thank you to the authors:Sara Lorenzoni, Carlos Rodríguez Nogales, Maria Blanco-Prieto 🎉 Special congratulations to Carlos Rodríguez Nogales on his new role as Assistant Professor at Universidad Complutense de Madrid! 🟰 Follow our LinkedIn posts for research highlights: https://lnkd.in/ecNd8VDP 🟰 Subscribe to our newsletter for cutting-edge insights: https://lnkd.in/eCyE3Pt2 🟰 Read our in-depth blogs on nanomedicine & innovation: https://lnkd.in/ekJ5cHDi 🟰 Exclusive expert interviews coming soon! https://lnkd.in/e-vkKBe8 🟰 Explore groundbreaking solutions from our collaborators: https://lnkd.in/eDbM9PWF 𝗜𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱 𝗶𝗻 𝗻𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲? 𝗙𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝘂𝗽𝗱𝗮𝘁𝗲𝘀! #nanosphere

The Next Generation of Vaccinologists at the ISV invites you to our upcoming webinar on Thursday, March 6th. We are excited to feature two presenters: Nicholas Tursi, PhD student, University of Pennsylvania Perelman School of Medicine Ilke Aernout, PhD student, Ghent University Webinar Time: 7:00 PST | 10:00 EST | 16:00 CET | 17:00 SAST | 20:30 IST | 02:00 AEDT Moderator: Dr. Allegra Peletta, Ghent University No registration is required. Just join via the Zoom link: https://lnkd.in/eMTSkdri We hope to see you there 😄

🟣 #CRISPR, #GeneTherapy, #Nanomedicine | 𝗖𝗮𝗻 𝘃𝗶𝗿𝘂𝘀-𝗹𝗶𝗸𝗲 𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴 𝗳𝗼𝗿 𝗛𝘂𝗻𝘁𝗶𝗻𝗴𝘁𝗼𝗻’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗼𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀? 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘷𝘪𝘳𝘶𝘴-𝘭𝘪𝘬𝘦 𝘱𝘢𝘳𝘵𝘪𝘤𝘭𝘦𝘴 (𝘝𝘓𝘗𝘴) 𝘥𝘦𝘭𝘪𝘷𝘦𝘳 𝘊𝘙𝘐𝘚𝘗𝘙–𝘊𝘢𝘴9 𝘸𝘪𝘵𝘩 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯, 𝘰𝘶𝘵𝘱𝘦𝘳𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘵𝘳𝘢𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘮𝘦𝘵𝘩𝘰𝘥𝘴. 𝗔𝗶𝗺: ✔️ To develop a customizable, cell-specific CRISPR–Cas9 delivery system (RIDE) for safer and more effective gene therapy. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ✔️ RIDE demonstrated efficiency comparable to AAV and lentiviral vectors, surpassing lipid nanoparticles. ✔️ Successfully reprogrammed to target dendritic cells, T cells, and neurons. ✔️ Significantly improved disease symptoms in ocular neovascular and Huntington’s disease models. ✔️ Efficiently edited the huntingtin gene in patient-derived neurons and was well tolerated in non-human primates. 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: ✔️ RIDE opens new doors for precise, cell-targeted CRISPR therapies, paving the way for safer and more effective treatments. Published in Nature Nanotechnology, February 10. Check here for more: https://lnkd.in/eKB4ev_6 Thank you to the authors: @Sikai Ling, Vicki Rui Xue Zhang, Dai Yao, @Zhuofan Jiang, @Xujiao Zhou, Sicong Lu, @Xiaoqing Qian, Jianping Liu, Niklas Selfjord, Tuğçe Munise Şatır Gustafsson, PhD, MBA, Anders Lundin, Julia liz touza, @Mike Firth, Natalie van Zuydam, Bilada Bilican, Pinar Akcakaya, @Jiaxu Hong & Yujia Cai. 🔬 Interested in the future of CRISPR therapeutics? Follow us for the latest updates! 🟰 𝗙𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗼𝘀𝘁𝘀 𝗳𝗼𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/ecNd8VDP 🟰 𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿 𝗳𝗼𝗿 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀: https://lnkd.in/eCyE3Pt2 🟰 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗯𝗹𝗼𝗴𝘀 𝗼𝗻 𝗻𝗮𝗻𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 & 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/ekJ5cHDi 🟰 𝗥𝗲𝗮𝗱 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 𝘄𝗶𝘁𝗵 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 (𝗺𝗮𝗻𝘆 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻!): https://lnkd.in/e-vkKBe8 🟰 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀: https://lnkd.in/eDbM9PWF

🟣 #ComputationalBiology, #AIinHealthcare, #CancerVaccine | 𝗖𝗮𝗻 𝗔𝗜 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗲 𝗺𝗥𝗡𝗔 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗱𝗲𝘀𝗶𝗴𝗻 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆? 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘴 𝘪𝘯 𝘣𝘪𝘰𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘤𝘴 𝘢𝘯𝘥 𝘈𝘐 𝘢𝘳𝘦 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘮𝘙𝘕𝘈 𝘷𝘢𝘤𝘤𝘪𝘯𝘦 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵, 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘥𝘦𝘴𝘪𝘨𝘯, 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘺, 𝘢𝘯𝘥 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺. 📘 𝗔𝗶𝗺: 🧬 This review explores how AI and computational biology enhance mRNA vaccine design, from neoantigen prediction to lipid nanoparticle (LNP) formulation, enabling more effective cancer immunotherapy. 📊 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 🤖 AI-driven tools improve the prediction of neoantigen structures, guiding mRNA sequence design for targeted immune responses. 💊 AI optimizes mRNA-LNP formulations, enhancing stability and delivery efficiency. 🔬 These innovations improve pharmacokinetics and pharmacodynamics, paving the way for personalized cancer vaccines. 📌 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: 🚀 AI and computational biology are accelerating the future of mRNA-based cancer immunotherapy, offering precision and scalability in vaccine development. Published in Frontiers in Cellular and Infection Microbiology, January 2025. Read more: https://lnkd.in/gTCV7sQz Thank you to the authors: Saber Imani Xiaoyan Liu Keyi Chen Mazaher Maghsoudloo Parham Jabbarzadeh Kaboli, Ph.D. Mehrdad Hashemi saloomeh khoushab @Xiaoping Li 🔎 Interested in AI-driven cancer immunotherapy? Follow us for the latest breakthroughs! #mRNAVaccines #AIinMedicine #PersonalizedTherapy #CancerResearch

🟣 #LNP #mRNA #DrugDelivery | 𝗛𝗼𝘄 𝗱𝗼 𝗺𝗶𝘅𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝗶𝗺𝗽𝗮𝗰𝘁 𝗟𝗡𝗣-𝗺𝗥𝗡𝗔 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆? 𝘓𝘪𝘱𝘪𝘥 𝘯𝘢𝘯𝘰𝘱𝘢𝘳𝘵𝘪𝘤𝘭𝘦𝘴 (𝘓𝘕𝘗𝘴) 𝘩𝘢𝘷𝘦 𝘳𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘻𝘦𝘥 𝘨𝘦𝘯𝘦𝘵𝘪𝘤 𝘮𝘢𝘵𝘦𝘳𝘪𝘢𝘭 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘺, 𝘣𝘶𝘵 𝘩𝘰𝘸 𝘥𝘰 𝘧𝘰𝘳𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘱𝘢𝘳𝘢𝘮𝘦𝘵𝘦𝘳𝘴 𝘪𝘯𝘧𝘭𝘶𝘦𝘯𝘤𝘦 𝘵𝘩𝘦𝘪𝘳 𝘤𝘩𝘢𝘳𝘢𝘤𝘵𝘦𝘳𝘪𝘴𝘵𝘪𝘤𝘴? 📘 𝗔𝗶𝗺: 🧪 This review explores LNP-mRNA production, focusing on mixing technologies, scalability challenges, and the impact of formulation & process parameters on LNP characteristics. 📊 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 🔬 LNPs are formed by self-assembly during rapid mixing of an aqueous mRNA phase and an organic lipid phase. ⚙️ Continuous methods, particularly T-shaped mixers, are the preferred technology for LNP-mRNA production. 📏 Scaling up from microfluidic chips to millimetric tubing presents challenges in maintaining mixing quality and nanoparticle consistency. 📌 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: 🚀 Optimizing mixing parameters is crucial for maintaining LNP-mRNA quality at scale, ensuring effective drug delivery. Published in International Journal of Pharmaceutics, March 2025 Check here for more: https://lnkd.in/e9h9sXiT Thank you to the authors: Laurine HOURDEL Noureddine Lebaz Florent PERAL Manon Ripoll @Stéphan Briançon Fethi BENSAID Sumit Luthra Claudia COGNE 🔗 Interested in LNP-mRNA delivery? Follow us for the latest insights! #Nanomedicine #Biopharma #mRNATechnology